联合检测MDR1/P-gp、C-erbB-2在乳腺癌中的表达及临床意义

目的 :联合检测乳腺癌患者中MDR1/P gp、及C erbB 2的表达 ,并探讨MDR1/P gp与C erbB 2的相关性。方法 :采用荧光定量RT PCR(FQ RT PCR)法检测 5 7例乳腺癌、2 0例对照组 (包括 10例乳腺良性疾病、10例癌旁正常组织 )中MDR1基因的表达 ,同时采用免疫组化法检测上述标本中P gp及C erbB 2蛋白的表达。 结果 :乳腺癌患者中MDR1基因扩增率及P gp蛋白阳性率分别为 5 0 .88% (2 9/ 5 7)和 4 2 .11% (2 4 / 5 7) ,与正常对照组相比均具有显著性差异 (P <0 .0 1)。MDR1基因扩增率高于P gp蛋白表达 ,二者呈高度相关 ,但并不完全相符 ;乳腺癌中C erbB 2过表达率为 2 8.0 7% (16 / 5 7) ,正常对照组中无C erbB 2蛋白过表达。MDR1/P gp阳性率与C erbB 2过表达呈正相关。结论 :乳腺癌中存在多药耐药基因MDR1及原癌基因C erbB 2的共表达 ,且其表达呈正相关。上述二种基因的表达 ,与乳腺癌的多药耐药有关。

Expression and clinical significance of MDR1/ P-gp, C-erbB-2 in breast cancer

Purpose:To detect the expression of MDR 1 / P-gp,C-erbB-2 in breast cancer and study the correlation between MDR 1 /P-gp and C-erbB-2. Methods:Expression of MDR 1 gene was measured with the flu orogenic quantitative RT-PCR method in 57 cases of breast cancer and 20 cases o f control group (including 10 cases of benign breast lesions and 10 cases of adj acent breast tissues). In addition, immunohistochemical analyses was used to det ect the expression of P-gp and C-erbB-2 protein in the above mentioned tissu es. Results:The amplification rate of MDR 1 gene and the expre ssion of P-gp protein in breast cancer group was 50.88% (29/57) and 42.11% (24/ 57), which had a significient difference as compared to the control group. The a mplification of MDR 1 gene were higher than the expression of P-gp protein ,there was close correlation between them but not complete correspondence.The p ositive rate was 28.07%(16/57) in detecting the overexpression of C-erbB-2 pro tein in breast cancer group, nevertheless, no positive case was found in the con trol group. The expression of MDR 1/P-gp was also correlated with the over expression of C-erbB-2. Conclusions:Multidrug resistance gene1(MDR 1)and protoonco gene C-erbB-2 were co-expressed in breast cancer,and their expression were po sitively related. The expression of above mentioned two genes have a relationshi p with multidrug resistance in breast cancer.